Ayesha Shaukat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ayesha Shaukat has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Aymar Akilimali
Faculty of Medicine University of Goma Goma DR Congo
10 shared publications - Rumaisa Riaz
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
7 shared publications - Laiba Shakeel
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
4 shared publications - Saad Ashraf
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
4 shared publications - Hamza Irfan
Department of Medicine Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College Lahore Pakistan
3 shared publications - Muhammad Shahmeer Ullah Shah
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
3 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Springer Nature in Thrombosis Journal
- Vol. 24 (1) , 93
Anticoagulation-associated hemorrhage in atrial fibrillation as a marker of occult malignancy: a narrative review
Atrial fibrillation (AF) is the most common arrhythmia in adults and significantly increases the risk of stroke. Due to common threats like systemic inflam
- 13 October 2026
- Published by Springer Nature in Thrombosis Journal
- Vol. 24 (1) , 93
Open AccessAnticoagulation-associated hemorrhage in atrial fibrillation as a marker of occult malignancy: a narrative review
Atrial fibrillation (AF) is the most common arrhythmia in adults and significantly increases the risk of stroke. Due to common threats like systemic inflam
- Open Access
- 18 August 2026
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (6) , 1712-1721
Reduced‐Port Versus Multi‐Port Laparoscopic Colectomy for Colorectal Cancer: A Systematic Review, Meta‐Analysis, and Meta‐Regression
Background: Reduced‐port laparoscopic colectomy (RPLC) has emerged as an alternative to multi‐port laparoscopic colectomy (MPLC) for colorectal cancer surgery, aiming to reduce operative morbidity and improve cosmetic outcomes. This systematic review and meta‐analysis evaluated and compared operative, postoperative, and oncologic outcomes between RPLC and MPLC. Methods: Following PRISMA guidelines, we systematically searched PubMed, Cochrane Library, ScienceDirect, and Google Scholar from inception to June 2025. The protocol was registered on PROSPERO (CRD420251078328). Included studies were randomized controlled trials (RCTs) or cohort studies comparing RPLC and MPLC. Primary outcomes were estimated blood loss, operative time, hospital stay, lymph node yield, and postoperative recovery indicators. Secondary outcomes included conversion rates, complications, and Clavien‐Dindo graded adverse events. Risk of bias was evaluated using the Newcastle‐Ottawa Scale and Cochrane RoB 2.0 tool. A random‐effects meta‐regression was performed to explore the impact of high‐stage tumors on the outcomes. Results: Thirteen studies ( n = 2897) were included. RPLC significantly reduced operative time (MD: −19.98 min; 95% CI: −29.73 to −10.24, p < 0.0001) and estimated blood loss (MD: −13.70 mL; 95% CI: −25.63 to −1.77, p = 0.02) without compromising hospital stay, lymph node yield, or complication rates. Meta‐regression revealed tumor stage significantly influenced operative time ( p = 0.0013). Conclusions: RPLC appears to provide comparable postoperative outcomes to MPLC with modest intraoperative advantages. As the evidence is largely retrospective and heterogeneous, these findings indicate the feasibility of RPLC rather than its superiority over MPLC. High‐quality clinical trials with longer follow‐up are required to confirm these findings and optimize clinical decision‐making. Trial Registration: PROSPERO registration ID: CRD420251078328
- 18 August 2026
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (6) , 1712-1721
Open AccessReduced‐Port Versus Multi‐Port Laparoscopic Colectomy for Colorectal Cancer: A Systematic Review, Meta‐Analysis, and Meta‐Regression
Background: Reduced‐port laparoscopic colectomy (RPLC) has emerged as an alternative to multi‐port laparoscopic colectomy (MPLC) for colorectal cancer surgery, aiming to reduce operative morbidity and improve cosmetic outcomes. This systematic review and meta‐analysis evaluated and compared operative, postoperative, and oncologic outcomes between RPLC and MPLC. Methods: Following PRISMA guidelines, we systematically searched PubMed, Cochrane Library, ScienceDirect, and Google Scholar from inception to June 2025. The protocol was registered on PROSPERO (CRD420251078328). Included studies were randomized controlled trials (RCTs) or cohort studies comparing RPLC and MPLC. Primary outcomes were estimated blood loss, operative time, hospital stay, lymph node yield, and postoperative recovery indicators. Secondary outcomes included conversion rates, complications, and Clavien‐Dindo graded adverse events. Risk of bias was evaluated using the Newcastle‐Ottawa Scale and Cochrane RoB 2.0 tool. A random‐effects meta‐regression was performed to explore the impact of high‐stage tumors on the outcomes. Results: Thirteen studies ( n = 2897) were included. RPLC significantly reduced operative time (MD: −19.98 min; 95% CI: −29.73 to −10.24, p < 0.0001) and estimated blood loss (MD: −13.70 mL; 95% CI: −25.63 to −1.77, p = 0.02) without compromising hospital stay, lymph node yield, or complication rates. Meta‐regression revealed tumor stage significantly influenced operative time ( p = 0.0013). Conclusions: RPLC appears to provide comparable postoperative outcomes to MPLC with modest intraoperative advantages. As the evidence is largely retrospective and heterogeneous, these findings indicate the feasibility of RPLC rather than its superiority over MPLC. High‐quality clinical trials with longer follow‐up are required to confirm these findings and optimize clinical decision‐making. Trial Registration: PROSPERO registration ID: CRD420251078328
- Open Access
- 22 June 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (6) , e72688
FDA Approval of Donanemab‐azbt: A New Dawn in Alzheimer's Disease Treatment
Background: Alzheimer's disease (AD) is a neurodegenerative condition marked by the accumulation of beta‐amyloid plaques and neurofibrillary tangles, leading to neuronal death and cognitive decline. Acetylcholinesterase inhibitors (AChEIs) such as donepezil, galantamine, and rivastigmine are commonly used to enhance cognitive function by increasing acetylcholine levels, but they can cause side effects like nausea, bradycardia, and headaches. NMDA receptor antagonists, like memantine, reduce glutamatergic activity and are used to manage symptoms, yet are also associated with adverse effects including dizziness and agitation. Recently, monoclonal antibodies such as aducanumab have been developed to target amyloid‐beta aggregates, though they are associated with amyloid‐related imaging abnormalities (ARIA). Aims: This article aims to summarize current pharmacological approaches to AD and to highlight the emerging role of Donanemab‐azbt, an FDA‐approved monoclonal antibody for early symptomatic AD, in reducing amyloid plaques and slowing cognitive decline. Methods: This overview synthesizes data from clinical trials and therapeutic experience with acetylcholinesterase inhibitors, NMDA receptor antagonists, and monoclonal antibodies, with a particular focus on Donanemab‐azbt, its mechanism of targeting amyloid‐beta aggregates, and its efficacy and safety profile in early symptomatic AD. Results: Donanemab‐azbt has demonstrated efficacy in clinical trials, significantly reducing amyloid plaque burden and slowing cognitive decline in patients with early symptomatic AD. However, its use may result in ARIA and other adverse effects, necessitating careful clinical and radiological monitoring during treatment. Conclusion: Despite the risks of ARIA and other adverse events, Donanemab‐azbt represents a promising addition to AD therapy, offering the potential for improved outcomes in patients with early symptomatic disease and expanding the therapeutic options beyond traditional symptomatic treatments.
- 22 June 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (6) , e72688
Open AccessFDA Approval of Donanemab‐azbt: A New Dawn in Alzheimer's Disease Treatment
Background: Alzheimer's disease (AD) is a neurodegenerative condition marked by the accumulation of beta‐amyloid plaques and neurofibrillary tangles, leading to neuronal death and cognitive decline. Acetylcholinesterase inhibitors (AChEIs) such as donepezil, galantamine, and rivastigmine are commonly used to enhance cognitive function by increasing acetylcholine levels, but they can cause side effects like nausea, bradycardia, and headaches. NMDA receptor antagonists, like memantine, reduce glutamatergic activity and are used to manage symptoms, yet are also associated with adverse effects including dizziness and agitation. Recently, monoclonal antibodies such as aducanumab have been developed to target amyloid‐beta aggregates, though they are associated with amyloid‐related imaging abnormalities (ARIA). Aims: This article aims to summarize current pharmacological approaches to AD and to highlight the emerging role of Donanemab‐azbt, an FDA‐approved monoclonal antibody for early symptomatic AD, in reducing amyloid plaques and slowing cognitive decline. Methods: This overview synthesizes data from clinical trials and therapeutic experience with acetylcholinesterase inhibitors, NMDA receptor antagonists, and monoclonal antibodies, with a particular focus on Donanemab‐azbt, its mechanism of targeting amyloid‐beta aggregates, and its efficacy and safety profile in early symptomatic AD. Results: Donanemab‐azbt has demonstrated efficacy in clinical trials, significantly reducing amyloid plaque burden and slowing cognitive decline in patients with early symptomatic AD. However, its use may result in ARIA and other adverse effects, necessitating careful clinical and radiological monitoring during treatment. Conclusion: Despite the risks of ARIA and other adverse events, Donanemab‐azbt represents a promising addition to AD therapy, offering the potential for improved outcomes in patients with early symptomatic disease and expanding the therapeutic options beyond traditional symptomatic treatments.
- Open Access
- 12 January 2026
- Published by Wiley in Critical Care Research and Practice
- Vol. 2026 (1)
Liberal Versus Restrictive Blood Transfusion Strategies in Neurocritical Care: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Introduction: Neurocritical care patients, including those with traumatic brain injury, subarachnoid hemorrhage, and intracerebral hemorrhage, often develop anemia, compromising brain oxygen delivery and increasing morbidity and mortality. Blood transfusion strategies, either liberal or restrictive, are commonly used to manage anemia in these patients, but the optimal approach remains unclear due to mixed results in existing studies. Methods: A systematic search of PubMed, Cochrane Library, ScienceDirect, and Google Scholar from inception to December 2024 for randomized controlled trials (RCTs) evaluating restrictive versus liberal transfusion strategies in adult neurocritical care patients. Outcomes included mortality, Glasgow Outcome Scale (GOS), red blood cell (RBC) units transfused, sepsis, intensive care unit (ICU)/hospital length of stay, and secondary complications. The study is registered with PROSPERO (CRD42025635426). Findings: The analysis included seven RCTs with 1941 patients. The restrictive strategy significantly reduced the number of RBC units transfused per patient (MD: 2.36; 95% CI: 1.08–3.64; p = 0.0003) and was associated with a lower incidence of sepsis (RR: 0.73; 95% CI: 0.56–0.96; p = 0.02). There were no significant differences between restrictive and liberal strategies for ICU (RR 0.74; 95% CI 0.28–1.91; p = 0.53), in‐hospital (RR 0.77; 95% CI 0.35–1.68), 30‐day (RR 0.91; 95% CI 0.70–1.18), 6‐month (RR 0.98; 95% CI 0.67–1.44), or long‐term mortality (RR 1.00; 95% CI 0.80–1.24). GOS scores at 6 months showed no significant difference (RR 0.94; 95% CI 0.83–1.07). ICU and hospital length of stay were also comparable between strategies. Secondary outcomes, including stroke, brain hypoxia, intracranial hypertension, and other non‐neurological complications, showed no significant differences between the two strategies. Conclusion: Restrictive transfusion strategies are as effective as liberal strategies in terms of mortality and neurological complications, with additional benefits such as fewer RBC transfusions and lower sepsis rates. These findings support restrictive strategies as a safer approach to managing anemia in neurocritical care, though further research on long‐term outcomes is needed.
- 12 January 2026
- Published by Wiley in Critical Care Research and Practice
- Vol. 2026 (1)
Open AccessLiberal Versus Restrictive Blood Transfusion Strategies in Neurocritical Care: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Introduction: Neurocritical care patients, including those with traumatic brain injury, subarachnoid hemorrhage, and intracerebral hemorrhage, often develop anemia, compromising brain oxygen delivery and increasing morbidity and mortality. Blood transfusion strategies, either liberal or restrictive, are commonly used to manage anemia in these patients, but the optimal approach remains unclear due to mixed results in existing studies. Methods: A systematic search of PubMed, Cochrane Library, ScienceDirect, and Google Scholar from inception to December 2024 for randomized controlled trials (RCTs) evaluating restrictive versus liberal transfusion strategies in adult neurocritical care patients. Outcomes included mortality, Glasgow Outcome Scale (GOS), red blood cell (RBC) units transfused, sepsis, intensive care unit (ICU)/hospital length of stay, and secondary complications. The study is registered with PROSPERO (CRD42025635426). Findings: The analysis included seven RCTs with 1941 patients. The restrictive strategy significantly reduced the number of RBC units transfused per patient (MD: 2.36; 95% CI: 1.08–3.64; p = 0.0003) and was associated with a lower incidence of sepsis (RR: 0.73; 95% CI: 0.56–0.96; p = 0.02). There were no significant differences between restrictive and liberal strategies for ICU (RR 0.74; 95% CI 0.28–1.91; p = 0.53), in‐hospital (RR 0.77; 95% CI 0.35–1.68), 30‐day (RR 0.91; 95% CI 0.70–1.18), 6‐month (RR 0.98; 95% CI 0.67–1.44), or long‐term mortality (RR 1.00; 95% CI 0.80–1.24). GOS scores at 6 months showed no significant difference (RR 0.94; 95% CI 0.83–1.07). ICU and hospital length of stay were also comparable between strategies. Secondary outcomes, including stroke, brain hypoxia, intracranial hypertension, and other non‐neurological complications, showed no significant differences between the two strategies. Conclusion: Restrictive transfusion strategies are as effective as liberal strategies in terms of mortality and neurological complications, with additional benefits such as fewer RBC transfusions and lower sepsis rates. These findings support restrictive strategies as a safer approach to managing anemia in neurocritical care, though further research on long‐term outcomes is needed.
- 19 August 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (4) , 2607-2617
Impact of Access Site in Percutaneous Coronary Intervention for Patients Complicated With Cardiogenic Shock: A Systematic Review and Meta‐Analysis of 33,311 Individuals
Background: Vascular access site selection remains critical in patients with cardiogenic shock (CS) undergoing percutaneous coronary intervention (PCI), with transradial access (TRA) increasingly favored for its potential safety benefits over transfemoral access (TFA). Methods: A systematic search of PubMed, Cochrane Library, and Science Direct was conducted from inception to March 2025. Meta‐analysis was performed using RevMan v5.3. Outcomes were reported as odds ratios (OR) with 95% confidence intervals (CI). Publication bias was assessed with funnel plots, Egger's test, and Begg's test using R software (version 4.5.0). Results: Thirteen studies comprising 33,311 patients were included. TRA illustrated significantly reduced in‐hospital mortality (OR: 0.45; 95% CI: 0.30–0.67; p < 0.0001), 30‐day mortality (OR: 0.57; 95% CI: 0.44–0.75; p < 0.0001), and 1‐year mortality (OR: 0.49; 95% CI: 0.40–0.60; p < 0.00001) compared to TFA. Major bleeding was significantly lower in the TRA group (OR: 0.53; 95% CI: 0.32–0.88; p = 0.01), as was the incidence of MACE (OR: 0.41; 95% CI: 0.25–0.68; p = 0.0004). No significant differences were observed in procedural success (OR: 0.73; 95% CI: 0.39–1.36; p = 0.32), contrast volume (MD: 6.95; 95% CI: −8.62 to 22.53; p = 0.38), or fluoroscopy time (MD: 0.11; 95% CI: −1.15 to 1.38; p = 0.86). Conclusion: TRA is associated with improved survival and safety outcomes in CS patients undergoing PCI, without compromising procedural efficiency. These findings support TRA as the preferred access strategy in experienced centers, though future long‐term studies are needed to validate these results.
- 19 August 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (4) , 2607-2617
Impact of Access Site in Percutaneous Coronary Intervention for Patients Complicated With Cardiogenic Shock: A Systematic Review and Meta‐Analysis of 33,311 Individuals
Background: Vascular access site selection remains critical in patients with cardiogenic shock (CS) undergoing percutaneous coronary intervention (PCI), with transradial access (TRA) increasingly favored for its potential safety benefits over transfemoral access (TFA). Methods: A systematic search of PubMed, Cochrane Library, and Science Direct was conducted from inception to March 2025. Meta‐analysis was performed using RevMan v5.3. Outcomes were reported as odds ratios (OR) with 95% confidence intervals (CI). Publication bias was assessed with funnel plots, Egger's test, and Begg's test using R software (version 4.5.0). Results: Thirteen studies comprising 33,311 patients were included. TRA illustrated significantly reduced in‐hospital mortality (OR: 0.45; 95% CI: 0.30–0.67; p < 0.0001), 30‐day mortality (OR: 0.57; 95% CI: 0.44–0.75; p < 0.0001), and 1‐year mortality (OR: 0.49; 95% CI: 0.40–0.60; p < 0.00001) compared to TFA. Major bleeding was significantly lower in the TRA group (OR: 0.53; 95% CI: 0.32–0.88; p = 0.01), as was the incidence of MACE (OR: 0.41; 95% CI: 0.25–0.68; p = 0.0004). No significant differences were observed in procedural success (OR: 0.73; 95% CI: 0.39–1.36; p = 0.32), contrast volume (MD: 6.95; 95% CI: −8.62 to 22.53; p = 0.38), or fluoroscopy time (MD: 0.11; 95% CI: −1.15 to 1.38; p = 0.86). Conclusion: TRA is associated with improved survival and safety outcomes in CS patients undergoing PCI, without compromising procedural efficiency. These findings support TRA as the preferred access strategy in experienced centers, though future long‐term studies are needed to validate these results.
- Open Access
- 9 August 2025
- Published by Springer Nature in BMC Neurology
- Vol. 25 (1) , 326
“The efficacy and safety of Atogepant for migraine prophylaxis: a systematic review and meta-analysis of randomized controlled trials”
Migraine is a complex neurological disorder characterized by recurrent, disabling headaches and various sensory symptoms, affecting about 15% of the global population annually. It is the second most common neurological condition worldwide, causing significant disability. While current prophylactic treatments include beta-blockers, tricyclic antidepressants, anticonvulsants, and monoclonal antibodies targeting the CGRP pathway, not all patients respond adequately. Atogepant, an oral CGRP receptor antagonist, has emerged as a promising option for migraine prevention with improved tolerability. This meta-analysis follows PRISMA guidelines, involving a comprehensive search of Cochrane CENTRAL, PubMed/MEDLINE, and Google Scholar databases up to July 2024. Efficacy outcomes included mean monthly migraine days (MMDs), mean monthly headache days (MHDs), monthly acute medication use days and the percentage of patients with a ≥ 50% reduction in MMDs. Safety outcomes were measured by adverse events (AEs). Statistical analysis employed the Inverse Variance and Mantel-Haenszel random-effects models, with heterogeneity assessed using the I² index. Six RCTs with 4325 patients (3054 on Atogepant, 1271 on placebo) met the inclusion criteria. The combined analysis indicated a significant reduction in MMDs favoring Atogepant over placebo (SMD - 0.39, 95% CI: -0.45 to -0.33; p < 0.00001; I²=0%). Similarly, significant reductions were observed in MHDs, monthly acute medication use days, and the proportion of patients achieving a ≥ 50% reduction in MMDs. Atogepant is an effective and safe option for migraine prophylaxis, showing significant reductions in MMDs. Further extensive trials are recommended to assess the long-term efficacy, safety, and cost efficiency of Atogepant compared to other preventive medications.
- 9 August 2025
- Published by Springer Nature in BMC Neurology
- Vol. 25 (1) , 326
Open Access“The efficacy and safety of Atogepant for migraine prophylaxis: a systematic review and meta-analysis of randomized controlled trials”
Migraine is a complex neurological disorder characterized by recurrent, disabling headaches and various sensory symptoms, affecting about 15% of the global population annually. It is the second most common neurological condition worldwide, causing significant disability. While current prophylactic treatments include beta-blockers, tricyclic antidepressants, anticonvulsants, and monoclonal antibodies targeting the CGRP pathway, not all patients respond adequately. Atogepant, an oral CGRP receptor antagonist, has emerged as a promising option for migraine prevention with improved tolerability. This meta-analysis follows PRISMA guidelines, involving a comprehensive search of Cochrane CENTRAL, PubMed/MEDLINE, and Google Scholar databases up to July 2024. Efficacy outcomes included mean monthly migraine days (MMDs), mean monthly headache days (MHDs), monthly acute medication use days and the percentage of patients with a ≥ 50% reduction in MMDs. Safety outcomes were measured by adverse events (AEs). Statistical analysis employed the Inverse Variance and Mantel-Haenszel random-effects models, with heterogeneity assessed using the I² index. Six RCTs with 4325 patients (3054 on Atogepant, 1271 on placebo) met the inclusion criteria. The combined analysis indicated a significant reduction in MMDs favoring Atogepant over placebo (SMD - 0.39, 95% CI: -0.45 to -0.33; p < 0.00001; I²=0%). Similarly, significant reductions were observed in MHDs, monthly acute medication use days, and the proportion of patients achieving a ≥ 50% reduction in MMDs. Atogepant is an effective and safe option for migraine prophylaxis, showing significant reductions in MMDs. Further extensive trials are recommended to assess the long-term efficacy, safety, and cost efficiency of Atogepant compared to other preventive medications.
- Open Access
- 31 July 2025
- Published by Springer Nature in Infection
- Vol. 53 (5) , 1645-1661
Efficacy and safety of Ensitrelvir in asymptomatic or mild to moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials
Introduction: Since late 2019, COVID-19 has had a catastrophic impact on public health. Ensitrelvir, a new antiviral targeting the SARS-CoV-2 main protease, has reduced viral replication and disease severity. This meta-analysis and systematic review assessed Ensitrelvir’s efficacy and safety in patients with mild-to-moderate COVID-19 symptoms. Methods: A comprehensive search was conducted in PubMed (Medline), Scopus, Embase, and CENTRAL up to July 2024 to retrieve randomized controlled trials (RCTs) comparing Ensitrelvir to placebo in adults with mild to moderate, RT-PCR–confirmed COVID-19. Outcomes were assessed at standardized time points, with viral RNA measured at day 4. Mean differences (MD) for continuous outcomes and risk ratios (RR) for binary outcomes, both with 95% confidence intervals (CIs), were calculated using the Mantel–Haenszel random-effects model. Efficacy outcomes included SARS-CoV-2 viral RNA, while safety outcomes included HDL, triglycerides, bilirubin, AST, headache, diarrhea, TEAEs, TRAEs, serious TEAEs, and treatment discontinuation. The quality of the included RCTs was assessed with the Cochrane Risk of Bias 2 (ROB2) tool. Results: The analysis included six RCTs with 2,793 participants: 1,860 received Ensitrelvir and 933 were given a placebo. Ensitrelvir gave significant results for reduced viral RNA levels of SARS-CoV-2 [MD: − 1.35; 95% CI − 1.58 to − 1.13; p < 0.01] and the incidence of lower cholesterol levels [RR: 8.83; 95% CI 4.05 to 19.27; p < 0.01] compared to the placebo group. However, it was associated with increased risks of decreased HDL levels, elevated triglycerides, increased bilirubin, more headaches, and a higher overall occurrence of treatment-emergent adverse events. Conclusion: Ensitrelvir effectively reduces viral load in COVID-19 patients, but its safety profile raises concerns due to significant adverse effects. The benefits must be carefully weighed against the risks, and further research is needed to confirm its role in treatment and to find ways to mitigate these adverse effects.
- 31 July 2025
- Published by Springer Nature in Infection
- Vol. 53 (5) , 1645-1661
Open AccessEfficacy and safety of Ensitrelvir in asymptomatic or mild to moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials
Introduction: Since late 2019, COVID-19 has had a catastrophic impact on public health. Ensitrelvir, a new antiviral targeting the SARS-CoV-2 main protease, has reduced viral replication and disease severity. This meta-analysis and systematic review assessed Ensitrelvir’s efficacy and safety in patients with mild-to-moderate COVID-19 symptoms. Methods: A comprehensive search was conducted in PubMed (Medline), Scopus, Embase, and CENTRAL up to July 2024 to retrieve randomized controlled trials (RCTs) comparing Ensitrelvir to placebo in adults with mild to moderate, RT-PCR–confirmed COVID-19. Outcomes were assessed at standardized time points, with viral RNA measured at day 4. Mean differences (MD) for continuous outcomes and risk ratios (RR) for binary outcomes, both with 95% confidence intervals (CIs), were calculated using the Mantel–Haenszel random-effects model. Efficacy outcomes included SARS-CoV-2 viral RNA, while safety outcomes included HDL, triglycerides, bilirubin, AST, headache, diarrhea, TEAEs, TRAEs, serious TEAEs, and treatment discontinuation. The quality of the included RCTs was assessed with the Cochrane Risk of Bias 2 (ROB2) tool. Results: The analysis included six RCTs with 2,793 participants: 1,860 received Ensitrelvir and 933 were given a placebo. Ensitrelvir gave significant results for reduced viral RNA levels of SARS-CoV-2 [MD: − 1.35; 95% CI − 1.58 to − 1.13; p < 0.01] and the incidence of lower cholesterol levels [RR: 8.83; 95% CI 4.05 to 19.27; p < 0.01] compared to the placebo group. However, it was associated with increased risks of decreased HDL levels, elevated triglycerides, increased bilirubin, more headaches, and a higher overall occurrence of treatment-emergent adverse events. Conclusion: Ensitrelvir effectively reduces viral load in COVID-19 patients, but its safety profile raises concerns due to significant adverse effects. The benefits must be carefully weighed against the risks, and further research is needed to confirm its role in treatment and to find ways to mitigate these adverse effects.
- Open Access
- 18 June 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (6) , e70920
Resmetirom: A Breakthrough in the Treatment of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)
Background and Aims: Metabolic dysfunction–associated steatotic liver disease (MASLD), previously referred to as non‐alcoholic fatty liver disease (NAFLD), has become the most prevalent chronic liver disease worldwide. Its increasing incidence is closely linked with rising rates of obesity, Type 2 diabetes mellitus (T2DM), and metabolic syndrome. MASLD includes a spectrum of liver pathologies such as fibrosis, cirrhosis, and metabolic dysfunction–associated steatohepatitis (MASH). This review explores diagnostic advancements and therapeutic developments, focusing on Resmetirom, a selective thyroid hormone receptor‐beta (THR‐β) agonist, as a novel pharmacologic intervention. Methods: The review draws upon current literature, clinical guidelines, and data from pivotal randomized controlled trials to evaluate the diagnostic criteria, non‐invasive assessment tools, lifestyle recommendations, and emerging pharmacotherapy for MASLD and MASH, focusing on Resmetirom. Results: Resmetirom has demonstrated significant efficacy in reducing hepatic fat content and improving markers of liver fibrosis in patients with noncirrhotic MASH and fibrosis stages F2–F3. Clinical trials showed improved liver histology, lipid profiles, and MASH resolution without fibrosis progression. Despite its promising profile, gastrointestinal side effects and gallstone‐related complications have been observed. Long‐term safety and outcomes related to cirrhosis or hepatocellular carcinoma prevention remain under investigation. Conclusion: MASLD is a significant public health concern driven by metabolic dysfunction. While lifestyle changes remain central to management, Resmetirom offers a promising pharmacological option for patients with moderate to advanced MASH. Further long‐term studies are needed to fully establish its safety, effectiveness, and role in preventing advanced liver disease.
- 18 June 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (6) , e70920
Open AccessResmetirom: A Breakthrough in the Treatment of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)
Background and Aims: Metabolic dysfunction–associated steatotic liver disease (MASLD), previously referred to as non‐alcoholic fatty liver disease (NAFLD), has become the most prevalent chronic liver disease worldwide. Its increasing incidence is closely linked with rising rates of obesity, Type 2 diabetes mellitus (T2DM), and metabolic syndrome. MASLD includes a spectrum of liver pathologies such as fibrosis, cirrhosis, and metabolic dysfunction–associated steatohepatitis (MASH). This review explores diagnostic advancements and therapeutic developments, focusing on Resmetirom, a selective thyroid hormone receptor‐beta (THR‐β) agonist, as a novel pharmacologic intervention. Methods: The review draws upon current literature, clinical guidelines, and data from pivotal randomized controlled trials to evaluate the diagnostic criteria, non‐invasive assessment tools, lifestyle recommendations, and emerging pharmacotherapy for MASLD and MASH, focusing on Resmetirom. Results: Resmetirom has demonstrated significant efficacy in reducing hepatic fat content and improving markers of liver fibrosis in patients with noncirrhotic MASH and fibrosis stages F2–F3. Clinical trials showed improved liver histology, lipid profiles, and MASH resolution without fibrosis progression. Despite its promising profile, gastrointestinal side effects and gallstone‐related complications have been observed. Long‐term safety and outcomes related to cirrhosis or hepatocellular carcinoma prevention remain under investigation. Conclusion: MASLD is a significant public health concern driven by metabolic dysfunction. While lifestyle changes remain central to management, Resmetirom offers a promising pharmacological option for patients with moderate to advanced MASH. Further long‐term studies are needed to fully establish its safety, effectiveness, and role in preventing advanced liver disease.
- Open Access
- 29 May 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (8) , 4963-4974
Integrating mental health and cardiovascular wellness: synergistic impacts and the promise of comprehensive care models
This review explores the bidirectional relationship between mental health disorders and cardiovascular disease (CVD), highlighting the potential of integrated healthcare models to improve outcomes. While CVD remains the leading cause of global mortality, traditionally linked to risk factors like hypertension and diabetes, emerging evidence shows that mental health conditions, especially depression and anxiety, significantly increase CVD risk through mechanisms such as chronic stress, inflammation, and neuroendocrine dysregulation. Activation of the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system exacerbates inflammation, elevates blood pressure, and contributes to cardiovascular risk factors. Moreover, the psychological burden of CVD often worsens mental health, creating a vicious cycle that complicates treatment adherence and patient management. Integrated care models offer a holistic approach to address these interconnected issues, potentially improving clinical outcomes, reducing healthcare costs, and enhancing patient adherence. This review also explores the role of telehealth and digital health interventions in overcoming accessibility barriers, particularly for underserved populations. Finally, policy recommendations emphasize the need for increased funding, professional training in interdisciplinary care, and targeted outreach to ensure equitable access to integrated care. By addressing both CVD and mental health challenges, these models could improve quality of life and reduce the global burden of these intertwined diseases.
- 29 May 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (8) , 4963-4974
Open AccessIntegrating mental health and cardiovascular wellness: synergistic impacts and the promise of comprehensive care models
This review explores the bidirectional relationship between mental health disorders and cardiovascular disease (CVD), highlighting the potential of integrated healthcare models to improve outcomes. While CVD remains the leading cause of global mortality, traditionally linked to risk factors like hypertension and diabetes, emerging evidence shows that mental health conditions, especially depression and anxiety, significantly increase CVD risk through mechanisms such as chronic stress, inflammation, and neuroendocrine dysregulation. Activation of the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system exacerbates inflammation, elevates blood pressure, and contributes to cardiovascular risk factors. Moreover, the psychological burden of CVD often worsens mental health, creating a vicious cycle that complicates treatment adherence and patient management. Integrated care models offer a holistic approach to address these interconnected issues, potentially improving clinical outcomes, reducing healthcare costs, and enhancing patient adherence. This review also explores the role of telehealth and digital health interventions in overcoming accessibility barriers, particularly for underserved populations. Finally, policy recommendations emphasize the need for increased funding, professional training in interdisciplinary care, and targeted outreach to ensure equitable access to integrated care. By addressing both CVD and mental health challenges, these models could improve quality of life and reduce the global burden of these intertwined diseases.